Liver steatosis in hepatitis C patients

World Journal of Hepatology

Volumn 7, Issue 10, 2015, Pages 1337-1346

  González Reimers, Emilio ^a   Quintero Platt, Geraldine ^a   Rodríguez Gaspar, Melchor ^a   Alemán Valls, Remedios ^a   Pérez Hernández, Onán ^a   Santolaria Fernández, Francisco ^a  

^a HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

Author keywords

Fatty acid oxidation; Hepatitis C virus steatosis adiponectin; Insulin resistance; Leptin; Proinflammatory cytokines; Triglyceride synthesis

Indexed keywords

EID: 84930411292     PISSN: None     EISSN: 19485182     Source Type: Journal    
DOI: 10.4254/wjh.v7.i10.1337     Document Type: Review

References (105)

1. Bugianesi E, Leone N, Vanni E, Marchesini G, Brunello F, Carucci P, Musso A, De Paolis P, Capussotti L, Salizzoni M, Rizzetto M. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002; 123: 134-140 [PMID: 12105842 DOI: 10.1053/gast. 2002.34168].
2. Hui E, Xu A, Bo Yang H, Lam KS. Obesity as the common soil of non-alcoholic fatty liver disease and diabetes: Role of adipokines. J Diabetes Investig 2013; 4: 413-425 [PMID: 24843689 DOI: 10.1111/jdi.12093].
3. Woreta TA, Sutcliffe CG, Mehta SH, Brown TT, Higgins Y, Thomas DL, Torbenson MS, Moore RD, Sulkowski MS. Incidence and risk factors for steatosis progression in adults coinfected with HIV and hepatitis C virus. Gastroenterology 2011; 140: 809-817 [PMID: 21134375 DOI: 10.1053/j.gastro.2010.11.052].
4. Lonardo A, Adinolfi LE, Loria P, Carulli N, Ruggiero G, Day CP. Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease. Gastroenterology 2004; 126: 586-597 [PMID: 14762795 DOI: 10.1053/j.gastro.2003.11.020].
5. Adinolfi LE, Gambardella M, Andreana A, Tripodi MF, Utili R, Ruggiero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001; 33: 1358-1364 [PMID: 11391523 DOI: 10.1053/jhep.2001.24432].
6. Kumar D, Farrell GC, Fung C, George J. Hepatitis C virus genotype 3 is cytopathic to hepatocytes: Reversal of hepatic steatosis after sustained therapeutic response. Hepatology 2002; 36: 1266-1272 [PMID: 12395339 DOI: 10.1053/jhep.2002.36370].
7. Jackel-Cram C, Babiuk LA, Liu Q. Up-regulation of fatty acid synthase promoter by hepatitis C virus core protein: genotype-3a core has a stronger effect than genotype-1b core. J Hepatol 2007; 46: 999-1008 [PMID: 17188392 DOI: 10.1016/j.jhep.2006.10.019].
8. Sato C, Saito T, Misawa K, Katsumi T, Tomita K, Ishii R, Haga H, Okumoto K, Nishise Y, Watanabe H, Ueno Y, Kawata S. Impaired mitochondrial β-oxidation in patients with chronic hepatitis C: relation with viral load and insulin resistance. BMC Gastroenterol 2013; 13: 112 [PMID: 23841691 DOI: 10.1186/1471-230X-13-112].
9. Perlemuter G, Sabile A, Letteron P, Vona G, Topilco A, Chrétien Y, Koike K, Pessayre D, Chapman J, Barba G, Bréchot C. Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral-related steatosis. FASEB J 2002; 16: 185-194 [PMID: 11818366 DOI: 10.1096/fj.01-0396com].
10. Goossens N, Negro F. The impact of obesity and metabolic syndrome on chronic hepatitis C. Clin Liver Dis 2014; 18: 147-156 [PMID: 24274870 DOI: 10.1016/j.cld.2013.09.007].
11. Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 2005; 115: 1343-1351 [PMID: 15864352 DOI: 10.1172/JCI23621].
12. Timlin MT, Parks EJ. Temporal pattern of de novo lipogenesis in the postprandial state in healthy men. Am J Clin Nutr 2005; 81: 35-42 [PMID: 15640457].
13. Tamura S, Shimomura I. Contribution of adipose tissue and de novo lipogenesis to nonalcoholic fatty liver disease. J Clin Invest 2005; 115: 1139-1142 [PMID: 15864343 DOI: 10.1172/JCI200524930].
14. Anderson N, Borlak J. Molecular mechanisms and therapeutic targets in steatosis and steatohepatitis. Pharmacol Rev 2008; 60: 311-357 [PMID: 18922966 DOI: 10.1124/pr.108.00001].
15. Shimomura I, Shimano H, Horton JD, Goldstein JL, Brown MS. Differential expression of exons 1a and 1c in mRNAs for sterol regulatory element binding protein-1 in human and mouse organs and cultured cells. J Clin Invest 1997; 99: 838-845 [PMID: 9062340 DOI: 10.1172/JCI119247].
16. Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 2002; 109: 1125-1131 [PMID: 11994399 DOI: 10.1172/JCI200215593].
17. Hannah VC, Ou J, Luong A, Goldstein JL, Brown MS. Unsaturated fatty acids down-regulate srebp isoforms 1a and 1c by two mechanisms in HEK-293 cells. J Biol Chem 2001; 276: 4365-4372 [PMID: 11085986 DOI: 10.1074/jbc.M007273200].
18. Shimomura I, Shimano H, Korn BS, Bashmakov Y, Horton JD. Nuclear sterol regulatory element-binding proteins activate genes responsible for the entire program of unsaturated fatty acid biosynthesis in transgenic mouse liver. J Biol Chem 1998; 273: 35299-35306 [PMID: 9857071 DOI: 10.1074/jbc.273.52.35299].
19. Shimano H, Horton JD, Hammer RE, Shimomura I, Brown MS, Goldstein JL. Overproduction of cholesterol and fatty acids causes massive liver enlargement in transgenic mice expressing truncated SREBP-1a. J Clin Invest 1996; 98: 1575-1584 [PMID: 8833906 DOI: 10.1172/JCI118951].
20. Shimomura I, Bashmakov Y, Ikemoto S, Horton JD, Brown MS, Goldstein JL. Insulin selectively increases SREBP-1c mRNA in the livers of rats with streptozotocin-induced diabetes. Proc Natl Acad Sci USA 1999; 96: 13656-13661 [PMID: 10570128 DOI: 10.1073/pnas.96.24.13656].
21. Shimano H, Horton JD, Shimomura I, Hammer RE, Brown MS, Goldstein JL. Isoform 1c of sterol regulatory element binding protein is less active than isoform 1a in livers of transgenic mice and in cultured cells. J Clin Invest 1997; 99: 846-854 [PMID: 9062341 DOI: 10.1172/JCI119248].
22. Baranowski M. Biological role of liver X receptors. J Physiol Pharmacol 2008; 59 Suppl 7: 31-55 [PMID: 19258656].
23. You M, Fischer M, Deeg MA, Crabb DW. Ethanol induces fatty acid synthesis pathways by activation of sterol regulatory elementbinding protein (SREBP). J Biol Chem 2002; 277: 29342-29347 [PMID: 12036955 DOI: 10.1074/jbc.M202411200].
24. Endo M, Masaki T, Seike M, Yoshimatsu H. TNF-alpha induces hepatic steatosis in mice by enhancing gene expression of sterol regulatory element binding protein-1c (SREBP-1c). Exp Biol Med (Maywood) 2007; 232: 614-621 [PMID: 17463157].
25. Bose SK, Kim H, Meyer K, Wolins N, Davidson NO, Ray R. Forkhead box transcription factor regulation and lipid accumulation by hepatitis C virus. J Virol 2014; 88: 4195-4203 [PMID: 24478438 DOI: 10.1128/JVI.03327-13].
26. Kim KH, Hong SP, Kim K, Park MJ, Kim KJ, Cheong J. HCV core protein induces hepatic lipid accumulation by activating SREBP1 and PPARgamma. Biochem Biophys Res Commun 2007; 355: 883-888 [PMID: 17331464 DOI: 10.1016/j.bbrc.2007.02.044].
27. Everitt H, Hu M, Ajmo JM, Rogers CQ, Liang X, Zhang R, Yin H, Choi A, Bennett ES, You M. Ethanol administration exacerbates the abnormalities in hepatic lipid oxidation in genetically obese mice. Am J Physiol Gastrointest Liver Physiol 2013; 304: G38-G47 [PMID: 23139221 DOI: 10.1152/ajpgi.00309.2012].
28. Ponugoti B, Kim DH, Xiao Z, Smith Z, Miao J, Zang M, Wu SY, Chiang CM, Veenstra TD, Kemper JK. SIRT1 deacetylates and inhibits SREBP-1C activity in regulation of hepatic lipid metabolism. J Biol Chem 2010; 285: 33959-33970 [PMID: 20817729 DOI: 10.1074/jbc.M110.122978].
29. Yu JW, Sun LJ, Liu W, Zhao YH, Kang P, Yan BZ. Hepatitis C virus core protein induces hepatic metabolism disorders through down-regulation of the SIRT1-AMPK signaling pathway. Int J Infect Dis 2013; 17: e539-e545 [PMID: 23510538 DOI: 10.1016/j.ijid.2013.01.027].
30. Shirwany NA, Zou MH. AMPK: a cellular metabolic and redox sensor. A minireview. Front Biosci (Landmark Ed) 2014; 19: 447-474 [PMID: 24389195].
31. Hou X, Xu S, Maitland-Toolan KA, Sato K, Jiang B, Ido Y, Lan F, Walsh K, Wierzbicki M, Verbeuren TJ, Cohen RA, Zang M. SIRT1 regulates hepatocyte lipid metabolism through activating AMPactivated protein kinase. J Biol Chem 2008; 283: 20015-20026 [PMID: 18482975 DOI: 10.1074/jbc.M802187200].
32. Alswat KA. The role of endocannabinoids system in fatty liver disease and therapeutic potentials. Saudi J Gastroenterol 2013; 19: 144-151 [PMID: 23828743 DOI: 10.4103/1319-3767.114505].
33. Osei-Hyiaman D, Liu J, Zhou L, Godlewski G, Harvey-White J, Jeong WI, Bátkai S, Marsicano G, Lutz B, Buettner C, Kunos G. Hepatic CB1 receptor is required for development of dietinduced steatosis, dyslipidemia, and insulin and leptin resistance in mice. J Clin Invest 2008; 118: 3160-3169 [PMID: 18677409 DOI: 10.1172/JCI34827].
34. Hézode C, Zafrani ES, Roudot-Thoraval F, Costentin C, Hessami A, Bouvier-Alias M, Medkour F, Pawlostky JM, Lotersztajn S, Mallat A. Daily cannabis use: a novel risk factor of steatosis severity in patients with chronic hepatitis C. Gastroenterology 2008; 134: 432-439 [PMID: 18242211 DOI: 10.1053/j. gastro.2007.11.039].
35. Sun LJ, Yu JW, Wan L, Zhang XY, Shi YG, Chen MY. Endocannabinoid system activation contributes to glucose metabolism disorders of hepatocytes and promotes hepatitis C virus replication. Int J Infect Dis 2014; 23: 75-81 [PMID: 24704332 DOI: 10.1016/j.ijid.2013.12.017].
36. Pai JT, Guryev O, Brown MS, Goldstein JL. Differential stimulation of cholesterol and unsaturated fatty acid biosynthesis in cells expressing individual nuclear sterol regulatory elementbinding proteins. J Biol Chem 1998; 273: 26138-26148 [PMID: 9748295 DOI: 10.1074/jbc.273.40.26138].
37. Denechaud PD, Dentin R, Girard J, Postic C. Role of ChREBP in hepatic steatosis and insulin resistance. FEBS Lett 2008; 582: 68-73 [PMID: 17716660 DOI: 10.1016/j.febslet.2007.07.084].
38. Ronis MJ, Mercer K, Suva LJ, Vantrease J, Ferguson M, Hogue WR, Sharma N, Cleves MA, Blackburn ML, Badger TM. Influence of fat/carbohydrate ratio on progression of fatty liver disease and on development of osteopenia in male rats fed alcohol via total enteral nutrition (TEN). Alcohol 2014; 48: 133-144 [PMID: 24581955 DOI: 10.1016/j.alcohol.2013.12.005].
39. Dentin R, Denechaud PD, Benhamed F, Girard J, Postic C. Hepatic gene regulation by glucose and polyunsaturated fatty acids: a role for ChREBP. J Nutr 2006; 136: 1145-1149 [PMID: 16614395].
40. Schadinger SE, Bucher NL, Schreiber BM, Farmer SR. PPARgamma2 regulates lipogenesis and lipid accumulation in steatotic hepatocytes. Am J Physiol Endocrinol Metab 2005; 288: E1195-E1205 [PMID: 15644454 DOI: 10.1152/ajpendo. 00513.2004].
41. Motomura W, Inoue M, Ohtake T, Takahashi N, Nagamine M, Tanno S, Kohgo Y, Okumura T. Up-regulation of ADRP in fatty liver in human and liver steatosis in mice fed with high fat diet. Biochem Biophys Res Commun 2006; 340: 1111-1118 [PMID: 16403437 DOI: 10.1016/j.bbrc.2005.12.121].
42. Bickel PE, Tansey JT, Welte MA. PAT proteins, an ancient family of lipid droplet proteins that regulate cellular lipid stores. Biochim Biophys Acta 2009; 1791: 419-440 [PMID: 19375517 DOI: 10.1016/j.bbalip.2009.04.002].
43. Lima-Cabello E, García-Mediavilla MV, Miquilena-Colina ME, Vargas-Castrillón J, Lozano-Rodríguez T, Fernández-Bermejo M, Olcoz JL, González-Gallego J, García-Monzón C, Sánchez-Campos S. Enhanced expression of pro-inflammatory mediators and liver X-receptor-regulated lipogenic genes in non-alcoholic fatty liver disease and hepatitis C. Clin Sci (Lond) 2011; 120: 239-250 [PMID: 20929443 DOI: 10.1042/CS20100387].
44. Reue K, Brindley DN. Thematic Review Series: Glycerolipids. Multiple roles for lipins/phosphatidate phosphatase enzymes in lipid metabolism. J Lipid Res 2008; 49: 2493-2503 [PMID: 18791037 DOI: 10.1194/jlr.R800019-JLR200].
45. Yen CL, Stone SJ, Koliwad S, Harris C, Farese RV. Thematic review series: glycerolipids. DGAT enzymes and triacylglycerol biosynthesis. J Lipid Res 2008; 49: 2283-2301 [PMID: 18757836 DOI: 10.1194/jlr.R800018-JLR200].
46. Finck BN, Gropler MC, Chen Z, Leone TC, Croce MA, Harris TE, Lawrence JC, Kelly DP. Lipin 1 is an inducible amplifier of the hepatic PGC-1alpha/PPARalpha regulatory pathway. Cell Metab 2006; 4: 199-210 [PMID: 16950137 DOI: 10.1016/j.cmet.2006.08.005].
47. Bechmann LP, Kocabayoglu P, Sowa JP, Sydor S, Best J, Schlattjan M, Beilfuss A, Schmitt J, Hannivoort RA, Kilicarslan A, Rust C, Berr F, Tschopp O, Gerken G, Friedman SL, Geier A, Canbay A. Free fatty acids repress small heterodimer partner (SHP) activation and adiponectin counteracts bile acid-induced liver injury in superobese patients with nonalcoholic steatohepatitis. Hepatology 2013; 57: 1394-1406 [PMID: 23299969 DOI: 10.1002/hep.26225].
48. Abdel-aleem S, Badr M, Perez-Tamayo RA, Anstadt MP, Lowe JE. Stimulation of myocyte insulin-responsive glucose transporters by the inhibition of fatty acid oxidation. Diabetes Res 1993; 22: 11-19 [PMID: 8200180].
49. Croce MA, Eagon JC, LaRiviere LL, Korenblat KM, Klein S, Finck BN. Hepatic lipin 1beta expression is diminished in insulinresistant obese subjects and is reactivated by marked weight loss. Diabetes 2007; 56: 2395-2399 [PMID: 17563064 DOI: 10.2337/db07-0480].
50. Reue K, Zhang P. The lipin protein family: dual roles in lipid biosynthesis and gene expression. FEBS Lett 2008; 582: 90-96 [PMID: 18023282 DOI: 10.1016/j.febslet.2007.11.014].
51. Hu M, Yin H, Mitra MS, Liang X, Ajmo JM, Nadra K, Chrast R, Finck BN, You M. Hepatic-specific lipin-1 deficiency exacerbates experimental alcohol-induced steatohepatitis in mice. Hepatology 2013; 58: 1953-1963 [PMID: 23787969 DOI: 10.1002/hep.26589].
52. Hu M, Wang F, Li X, Rogers CQ, Liang X, Finck BN, Mitra MS, Zhang R, Mitchell DA, You M. Regulation of hepatic lipin-1 by ethanol: role of AMP-activated protein kinase/sterol regulatory element-binding protein 1 signaling in mice. Hepatology 2012; 55: 437-446 [PMID: 21953514 DOI: 10.1002/hep.24708].
53. Yin H, Hu M, Liang X, Ajmo JM, Li X, Bataller R, Odena G, Stevens SM, You M. Deletion of SIRT1 from hepatocytes in mice disrupts lipin-1 signaling and aggravates alcoholic fatty liver. Gastroenterology 2014; 146: 801-811 [PMID: 24262277 DOI: 10.1053/j.gastro.2013.11.008].
54. García-Villafranca J, Guillén A, Castro J. Ethanol consumption impairs regulation of fatty acid metabolism by decreasing the activity of AMP-activated protein kinase in rat liver. Biochimie 2008; 90: 460-466 [PMID: 17997005 DOI: 10.1016/j.biochi.2007.09.019].
55. Denechaud PD, Girard J, Postic C. Carbohydrate responsive element binding protein and lipid homeostasis. Curr Opin Lipidol 2008; 19: 301-306 [PMID: 18460923 DOI: 10.1097/MOL. 0b013e 3282ffafaa].
56. Saltiel AR, Kahn CR. Insulin signalling and the regulation of glucose and lipid metabolism. Nature 2001; 414: 799-806 [PMID: 11742412 DOI: 10.1038/414799a].
57. Rui L. Energy metabolism in the liver. Compr Physiol 2014; 4: 177-197 [PMID: 24692138 DOI: 10.1002/cphy.c130024].
58. Wolfrum C, Stoffel M. Coactivation of Foxa2 through Pgc-1beta promotes liver fatty acid oxidation and triglyceride/VLDL secretion. Cell Metab 2006; 3: 99-110 [PMID: 16459311 DOI: 10.1016/j.cmet.2006.01.001].
59. Brown MS, Goldstein JL. Selective versus total insulin resistance: a pathogenic paradox. Cell Metab 2008; 7: 95-96 [PMID: 18249166 DOI: 10.1016/j.cmet.2007.12.009].
60. Sparks JD, Sparks CE, Adeli K. Selective hepatic insulin resistance, VLDL overproduction, and hypertriglyceridemia. Arterioscler Thromb Vasc Biol 2012; 32: 2104-2112 [PMID: 22796579 DOI: 10.1161/ATVBAHA.111.241463].
61. Wang Y, Tran K, Yao Z. The activity of microsomal triglyceride transfer protein is essential for accumulation of triglyceride within microsomes in McA-RH7777 cells. A unified model for the assembly of very low density lipoproteins. J Biol Chem 1999; 274: 27793-27800 [PMID: 10488124 DOI: 10.1074/jbc.274.39.27793].
62. Kamagate A, Qu S, Perdomo G, Su D, Kim DH, Slusher S, Meseck M, Dong HH. FoxO1 mediates insulin-dependent regulation of hepatic VLDL production in mice. J Clin Invest 2008; 118: 2347-2364 [PMID: 18497885 DOI: 10.1172/JCI32914].
63. Mirandola S, Bowman D, Hussain MM, Alberti A. Hepatic steatosis in hepatitis C is a storage disease due to HCV interaction with microsomal triglyceride transfer protein (MTP). Nutr Metab (Lond) 2010; 7: 13 [PMID: 20178560 DOI: 10.1186/1743-7075-7-13].
64. Huang J, Iqbal J, Saha PK, Liu J, Chan L, Hussain MM, Moore DD, Wang L. Molecular characterization of the role of orphan receptor small heterodimer partner in development of fatty liver. Hepatology 2007; 46: 147-157 [PMID: 17526026 DOI: 10.1002/hep.21632].
65. Wu C, Gilroy R, Taylor R, Olyaee M, Abdulkarim B, Forster J, O'Neil M, Damjanov I, Wan YJ. Alteration of hepatic nuclear receptor-mediated signaling pathways in hepatitis C virus patients with and without a history of alcohol drinking. Hepatology 2011; 54: 1966-1974 [PMID: 21898497 DOI: 10.1002/hep.24645].
66. Del Campo JA, Romero-Gómez M. Steatosis and insulin resistance in hepatitis C: a way out for the virus?. World J Gastroenterol 2009; 15: 5014-5019 [PMID: 19859993 DOI: 10.3748/wjg.15.5014].
67. White DL, Ratziu V, El-Serag HB. Hepatitis C infection and risk of diabetes: a systematic review and meta-analysis. J Hepatol 2008; 49: 831-844 [PMID: 18814931 DOI: 10.1016/j.jhep.2008.08.006].
68. Parvaiz F, Manzoor S, Iqbal J, McRae S, Javed F, Ahmed QL, Waris G. Hepatitis C virus nonstructural protein 5A favors upregulation of gluconeogenic and lipogenic gene expression leading towards insulin resistance: a metabolic syndrome. Arch Virol 2014; 159: 1017-1025 [PMID: 24240483 DOI: 10.1007/s00705-013-1892-3].
69. Jung HJ, Kim YS, Kim SG, Lee YN, Jeong SW, Jang JY, Lee SH, Kim HS, Kim BS. The impact of pegylated interferon and ribavirin combination treatment on lipid metabolism and insulin resistance in chronic hepatitis C patients. Clin Mol Hepatol 2014; 20: 38-46 [PMID: 24757657 DOI: 10.3350/cmh.2014.20.1.38].
70. García-Mediavilla MV, Pisonero-Vaquero S, Lima-Cabello E, Benedicto I, Majano PL, Jorquera F, González-Gallego J, Sánchez-Campos S. Liver X receptor α-mediated regulation of lipogenesis by core and NS5A proteins contributes to HCV-induced liver steatosis and HCV replication. Lab Invest 2012; 92: 1191-1202 [PMID: 22641099 DOI: 10.1038/labinvest.2012.88].
71. Moucari R, Asselah T, Cazals-Hatem D, Voitot H, Boyer N, Ripault MP, Sobesky R, Martinot-Peignoux M, Maylin S, Nicolas-Chanoine MH, Paradis V, Vidaud M, Valla D, Bedossa P, Marcellin P. Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis. Gastroenterology 2008; 134: 416-423 [PMID: 18164296 DOI: 10.1053/j.gastro.2007.11.010].
72. Neuschwander-Tetri BA. Hepatitis C virus-induced insulin resistance: not all genotypes are the same. Gastroenterology 2008; 134: 619-622 [PMID: 18242225 DOI: 10.1053/j.gastro.2007.12.041].
73. Pazienza V, Clément S, Pugnale P, Conzelman S, Foti M, Mangia A, Negro F. The hepatitis C virus core protein of genotypes 3a and 1b downregulates insulin receptor substrate 1 through genotypespecific mechanisms. Hepatology 2007; 45: 1164-1171 [PMID: 17465001 DOI: 10.1002/hep.21634].
74. Fisher TL, White MF. Signaling pathways: the benefits of good communication. Curr Biol 2004; 14: R1005-R1007 [PMID: 15589136 DOI: 10.1016/j.cub.2004.11.024].
75. Laplante M, Sabatini DM. An emerging role of mTOR in lipid biosynthesis. Curr Biol 2009; 19: R1046-R1052 [PMID: 19948145 DOI: 10.1016/j.cub.2009.09.058].
76. Hung CH, Lee CM, Chen CH, Hu TH, Jiang SR, Wang JH, Lu SN, Wang PW. Association of inflammatory and anti-inflammatory cytokines with insulin resistance in chronic hepatitis C. Liver Int 2009; 29: 1086-1093 [PMID: 19302182 DOI: 10.1111/j. 1478-3231 .2009.01991.x].
77. Maury E, Ehala-Aleksejev K, Guiot Y, Detry R, Vandenhooft A, Brichard SM. Adipokines oversecreted by omental adipose tissue in human obesity. Am J Physiol Endocrinol Metab 2007; 293: E656-E665 [PMID: 17578888 DOI: 10.1152/ajpendo.00127.2007].
78. Snijder MB, Flyvbjerg A, Stehouwer CD, Frystyk J, Henry RM, Seidell JC, Heine RJ, Dekker JM. Relationship of adiposity with arterial stiffness as mediated by adiponectin in older men and women: the Hoorn Study. Eur J Endocrinol 2009; 160: 387-395 [PMID: 19095778 DOI: 10.1530/EJE-08-0817].
79. Wu H, Qi Q, Yu Z, Sun Q, Wang J, Franco OH, Sun L, Li H, Liu Y, Hu FB, Lin X. Independent and opposite associations of trunk and leg fat depots with adipokines, inflammatory markers, and metabolic syndrome in middle-aged and older Chinese men and women. J Clin Endocrinol Metab 2010; 95: 4389-4398 [PMID: 20519350 DOI: 10.1210/jc.2010-0181].
80. Ashour E, Samy N, Sayed M, Imam A. The relationship between serum adiponectin and steatosis in patients with chronic hepatitis C genotype-4. Clin Lab 2010; 56: 103-110 [PMID: 20476641].
81. Cua IH, Hui JM, Bandara P, Kench JG, Farrell GC, McCaughan GW, George J. Insulin resistance and liver injury in hepatitis C is not associated with virus-specific changes in adipocytokines. Hepatology 2007; 46: 66-73 [PMID: 17596870 DOI: 10.1002/hep.21703].
82. Tiftikci A, Atug O, Yilmaz Y, Eren F, Ozdemir FT, Yapali S, Ozdogan O, Celikel CA, Imeryuz N, Tozun N. Serum levels of adipokines in patients with chronic HCV infection: relationship with steatosis and fibrosis. Arch Med Res 2009; 40: 294-298 [PMID: 19608019 DOI: 10.1016/j.arcmed.2009.04.008].
83. Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, Yamashita S, Noda M, Kita S, Ueki K, Eto K, Akanuma Y, Froguel P, Foufelle F, Ferre P, Carling D, Kimura S, Nagai R, Kahn BB, Kadowaki T. Adiponectin stimulates glucose utilization and fattyacid oxidation by activating AMP-activated protein kinase. Nat Med 2002; 8: 1288-1295 [PMID: 12368907].
84. Chen H, Zhang L, Li X, Li X, Sun G, Yuan X, Lei L, Liu J, Yin L, Deng Q, Wang J, Liu Z, Yang W, Wang Z, Zhang H, Liu G. Adiponectin activates the AMPK signaling pathway to regulate lipid metabolism in bovine hepatocytes. J Steroid Biochem Mol Biol 2013; 138: 445-454 [PMID: 23994141 DOI: 10.1016/j. jsbmb.2013.08.013].
85. Matsunami T, Sato Y, Ariga S, Sato T, Shimomura T, Kashimura H, Hasegawa Y, Yukawa M. Regulation of synthesis and oxidation of fatty acids by adiponectin receptors (AdipoR1/R2) and insulin receptor substrate isoforms (IRS-1/-2) of the liver in a nonalcoholic steatohepatitis animal model. Metabolism 2011; 60: 805-814 [PMID: 20846698 DOI: 10.1016/j.metabol.2010.07.032].
86. Masaki T, Chiba S, Tatsukawa H, Yasuda T, Noguchi H, Seike M, Yoshimatsu H. Adiponectin protects LPS-induced liver injury through modulation of TNF-alpha in KK-Ay obese mice. Hepatology 2004; 40: 177-184 [PMID: 15239101 DOI: 10.1002/hep.20282].
87. Yoon MJ, Lee GY, Chung JJ, Ahn YH, Hong SH, Kim JB. Adiponectin increases fatty acid oxidation in skeletal muscle cells by sequential activation of AMP-activated protein kinase, p38 mitogen-activated protein kinase, and peroxisome proliferatoractivated receptor alpha. Diabetes 2006; 55: 2562-2570 [PMID: 16936205 DOI: 10.2337/db05-1322].
88. Hong F, Radaeva S, Pan HN, Tian Z, Veech R, Gao B. Interleukin 6. alleviates hepatic steatosis and ischemia/reperfusion injury in mice with fatty liver disease. Hepatology 2004; 40: 933-941 [PMID: 15382116 DOI: 10.1002/hep.20400].
89. Chen L, Yang G. PPARs Integrate the Mammalian Clock and Energy Metabolism. PPAR Res 2014; 2014: 653017 [PMID: 24693278].
90. Ip E, Farrell GC, Robertson G, Hall P, Kirsch R, Leclercq I. Central role of PPARalpha-dependent hepatic lipid turnover in dietary steatohepatitis in mice. Hepatology 2003; 38: 123-132 [PMID: 12829994 DOI: 10.1053/jhep.2003.50307].
91. Fischer M, You M, Matsumoto M, Crabb DW. Peroxisome proliferator-activated receptor alpha (PPARalpha) agonist treatment reverses PPARalpha dysfunction and abnormalities in hepatic lipid metabolism in ethanol-fed mice. J Biol Chem 2003; 278: 27997-28004 [PMID: 12791698 DOI: 10.1074/jbc.M302140200].
92. Yamaguchi A, Tazuma S, Nishioka T, Ohishi W, Hyogo H, Nomura S, Chayama K. Hepatitis C virus core protein modulates fatty acid metabolism and thereby causes lipid accumulation in the liver. Dig Dis Sci 2005; 50: 1361-1371 [PMID: 16047488 DOI: 10.1007/s10620-005-2788-1].
93. Singaravelu R, Chen R, Lyn RK, Jones DM, O'Hara S, Rouleau Y, Cheng J, Srinivasan P, Nasheri N, Russell RS, Tyrrell DL, Pezacki JP. Hepatitis C virus induced up-regulation of microRNA-27: a novel mechanism for hepatic steatosis. Hepatology 2014; 59: 98-108 [PMID: 23897856 DOI: 10.1002/hep.26634].
94. Wang J, Leclercq I, Brymora JM, Xu N, Ramezani-Moghadam M, London RM, Brigstock D, George J. Kupffer cells mediate leptin-induced liver fibrosis. Gastroenterology 2009; 137: 713-723 [PMID: 19375424 DOI: 10.1053/j.gastro.2009.04.011].
95. Myers MG, Cowley MA, Münzberg H. Mechanisms of leptin action and leptin resistance. Annu Rev Physiol 2008; 70: 537-556 [PMID: 17937601 DOI: 10.1146/annurev.physiol.70.113006.100707].
96. Kukla M, Mazur W, Buldak RJ, Zwirska-Korczala K. Potential role of leptin, adiponectin and three novel adipokines-visfatin, chemerin and vaspin-in chronic hepatitis. Mol Med 2011; 17: 1397-1410 [PMID: 21738955 DOI: 10.2119/molmed.2010.00105].
97. Giannini E, Ceppa P, Botta F, Mastracci L, Romagnoli P, Comino I, Pasini A, Risso D, Lantieri PB, Icardi G, Barreca T, Testa R. Leptin has no role in determining severity of steatosis and fibrosis in patients with chronic hepatitis C. Am J Gastroenterol 2000; 95: 3211-3217 [PMID: 11095344 DOI: 10.1111/j. 1572-0241.2000.032 94.x].
98. Testa R, Franceschini R, Giannini E, Cataldi A, Botta F, Fasoli A, Tenerelli P, Rolandi E, Barreca T. Serum leptin levels in patients with viral chronic hepatitis or liver cirrhosis. J Hepatol 2000; 33: 33-37 [PMID: 10905583 DOI: 10.1016/S0168-8278(00)80156-7].
99. Myers RP, Messous D, Poynard T, Imbert-Bismut F. Association between leptin, metabolic factors and liver histology in patients with chronic hepatitis C. Can J Gastroenterol 2007; 21: 289-294 [PMID: 17505564].
100. Crespo J, Rivero M, Fábrega E, Cayón A, Amado JA, García-Unzeta MT, Pons-Romero F. Plasma leptin and TNF-alpha levels in chronic hepatitis C patients and their relationship to hepatic fibrosis. Dig Dis Sci 2002; 47: 1604-1610 [PMID: 12141823].
101. Begriche K, Massart J, Robin MA, Bonnet F, Fromenty B. Mitochondrial adaptations and dysfunctions in nonalcoholic fatty liver disease. Hepatology 2013; 58: 1497-1507 [PMID: 23299992 DOI: 10.1002/hep.26226].
102. Sonnenberg GE, Krakower GR, Kissebah AH. A novel pathway to the manifestations of metabolic syndrome. Obes Res 2004; 12: 180-186 [PMID: 14981209 DOI: 10.1038/oby.2004.24].
103. Sheikh MY, Choi J, Qadri I, Friedman JE, Sanyal AJ. Hepatitis C virus infection: molecular pathways to metabolic syndrome. Hepatology 2008; 47: 2127-2133 [PMID: 18446789 DOI: 10.1002/hep.22269].
104. Gong G, Waris G, Tanveer R, Siddiqui A. Human hepatitis C virus NS5A protein alters intracellular calcium levels, induces oxidative stress, and activates STAT-3 and NF-kappa B. Proc Natl Acad Sci USA 2001; 98: 9599-9604 [PMID: 11481452 DOI: 10.1073/pnas.171311298].
105. Choi SH, Park KJ, Ahn BY, Jung G, Lai MM, Hwang SB. Hepatitis C virus nonstructural 5B protein regulates tumor necrosis factor alpha signaling through effects on cellular IkappaB kinase. Mol Cell Biol 2006; 26: 3048-3059 [PMID: 16581780 DOI: 10.1128/MCB.26.8.3048-3059.2006].